Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule-Reference-Cited by-同舟云学术

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

Published:2015-09-04 Issue:6 Volume:7 Page:1205-1211
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Gatault Philippe,Brachet Guillaume,Ternant David,Degenne Danielle,Récipon Guillaume,Barbet Christelle,Gyan Emmanuel,Gouilleux-Gruart Valérie,Bordes Cécile,Farrell Alexandra,Halimi Jean Michel,Watier Hervé

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/19420862.2015.1086049

Reference17 articles.

1. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv

2. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

3. Eculizumab fails to inhibit generation of C5a in vivo

4. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

5. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms;Drug Discovery Today;2024-09

2. Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature;Expert Review of Hematology;2024-06-12

3. External quality assurance program for diagnostic complement laboratories: evaluation of the results of the past seven years;Frontiers in Immunology;2024-03-26

4. Complement Blockade, a New Therapeutic Approach in Malignant Hypertension;Internal Medicine;2024-03-01

5. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics;British Journal of Clinical Pharmacology;2024-02-19